Literature DB >> 21275942

Management of palmoplantar pustulosis: do we need to change?

U Mrowietz1, P C M van de Kerkhof.   

Abstract

Palmoplantar pustulosis (PPP) is difficult to treat. There is little hard evidence for the efficacy of any treatment and no published guidelines for its management. A number of exacerbating factors are well documented and there is some evidence for the importance of others. Smoking is the most recognized environmental trigger and recent research has concentrated on the role of eccrine sweat glands in this regard. Other factors, including tonsillar streptococcal infection and gluten sensitivity, may be important in selected cases. The aim of this review is to challenge dermatologists to consider alternative management strategies for PPP and design clinical trials that will enable the development of useful therapeutic guidelines.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2011        PMID: 21275942     DOI: 10.1111/j.1365-2133.2011.10233.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

1.  Pustulosis palmaris et plantaris.

Authors:  Gunalp Uzun; Ercan Karabacak; Mesut Mutluoglu; Ersin Aydin
Journal:  BMJ Case Rep       Date:  2013-05-24

2.  Palmoplantar pustulosis.

Authors:  David A Wetter
Journal:  CMAJ       Date:  2012-12-03       Impact factor: 8.262

3.  UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study.

Authors:  Li-Na Su; Jie Ren; Shi-Meng Cheng; Jian-Lan Liu; Yang-Feng Ding; Ning-Wen Zhu
Journal:  Lasers Med Sci       Date:  2017-07-11       Impact factor: 3.161

4.  Throat Infections are Associated with Exacerbation in a Substantial Proportion of Patients with Chronic Plaque Psoriasis.

Authors:  Ragna H Thorleifsdottir; Jenna H Eysteinsdóttir; Jón H Olafsson; Martin I Sigurdsson; Andrew Johnston; Helgi Valdimarsson; Bardur Sigurgeirsson
Journal:  Acta Derm Venereol       Date:  2016-08-23       Impact factor: 4.437

Review 5.  Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders.

Authors:  Hajime Sasaki; Kimito Hirai; Christine M Martins; Hisako Furusho; Ricardo Battaglino; Koshi Hashimoto
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

6.  Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.

Authors:  Tadashi Terui; Satomi Kobayashi; Yukari Okubo; Masamoto Murakami; Keiichiro Hirose; Hiroshi Kubo
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

7.  Novel application of high-dose rate brachytherapy for severe, recalcitrant palmoplantar pustulosis.

Authors:  D Timerman; P M Devlin; V E Nambudiri; N A Wright; R A Vleugels; R A Clark; T S Kupper; J F Merola; M Patel
Journal:  Clin Exp Dermatol       Date:  2016-02-05       Impact factor: 3.470

8.  Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris.

Authors:  Robert Bissonnette; Mayte Suárez-Fariñas; Xuan Li; Kathleen M Bonifacio; Carrie Brodmerkel; Judilyn Fuentes-Duculan; James G Krueger
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

9.  Microscopic Examination of Nail Clippings from Patients with Palmoplantar Pustulosis.

Authors:  Anber Ancel Tanaka; Betina Werner; Cassia Farris; Cassio Tornesy
Journal:  Dermatopathology (Basel)       Date:  2019-10-29

10.  Insulin resistance, diabetes mellitus and thyroid dysfunction in patients with palmoplantar pustulosis: a case-controlled study.

Authors:  Hatice Ataş; Müzeyyen Gönül
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.